Narin Sriratanaviriyakul, MD
Internal Medicine · Carmichael, CANPI 1194952010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,150 and has fallen 88.4% since, to $249 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $74.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Genentech USA, Inc.$876
- GSK$470
- Eisai Inc.$442
- Boehringer Ingelheim$270
- Insmed, Inc.$258
- plus $3K from 18 others
What the payments were for
- Food & beverage$5,97896%
- Education$2294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $1,238 |
| Genentech USA, Inc. | 7 | $876 |
| GSK | 17 | $470 |
| Eisai Inc. | 4 | $442 |
| Boehringer Ingelheim | 4 | $270 |
| Insmed, Inc. | 4 | $258 |
| Incyte Corporation | 2 | $239 |
| Beigene USA, Inc. | 2 | $237 |
| Sanofi | 3 | $235 |
| AbbVie | 8 | $208 |
| Amgen | 2 | $200 |
| Regeneron Healthcare Solutions, Inc. | 3 | $146 |
| Stryker | 1 | $127 |
| IBSA Pharma Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Mylan Specialty L.p. | 1 | $124 |
| Pfizer | 1 | $123 |
| Agios Pharmaceuticals, Inc. | 1 | $122 |
| Gilead | 1 | $122 |
| Neurocrine Biosciences, Inc. | 1 | $122 |
| Johnson & Johnson | 1 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $110 |
| Daiichi Sankyo Inc. | 1 | $103 |
| Novo Nordisk | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,207 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Carmichael
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.